Journal article
Nanoparticle vaccines against respiratory syncytial virus
Future virology, Vol.15(11), pp.763-778
11/2020
DOI: 10.2217/fvl-2020-0174
PMCID: PMC7737143
PMID: 33343684
Abstract
Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in infants, the elderly and immunocompromised individuals. Despite the global burden, there is no licensed vaccine for RSV. Recent advances in the use of nanoparticle technology have provided new opportunities to address some of the limitations of conventional vaccines. Precise control over particle size and surface properties enhance antigen stability and prolong antigen release. Particle size can also be modified to target specific antigen-presenting cells in order to induce specific types of effector T-cell responses. Numerous nanoparticle-based vaccines are currently being evaluated for RSV including inorganic, polymeric and virus-like particle-based formulations. Here, we review the potential advantages of using different nanoparticle formulations in a vaccine for RSV, and discuss many examples of safe, and effective vaccines currently in both preclinical and clinical stages of testing.
Details
- Title: Subtitle
- Nanoparticle vaccines against respiratory syncytial virus
- Creators
- Laura M Stephens - Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA 52242, USASteven M Varga - Department of Pathology, University of Iowa, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- Future virology, Vol.15(11), pp.763-778
- Publisher
- England
- DOI
- 10.2217/fvl-2020-0174
- PMID
- 33343684
- PMCID
- PMC7737143
- ISSN
- 1746-0794
- eISSN
- 1746-0808
- Grant note
- T32 AI007485 / NIAID NIH HHS
- Language
- English
- Date published
- 11/2020
- Academic Unit
- Graduate College Admin and Gen; Microbiology and Immunology; Pathology
- Record Identifier
- 9984066346302771
Metrics
19 Record Views